
AgomAb Therapeutics NV (NASDAQ:AGMB – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings per share estimates for AgomAb Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.87) per share for the year, up from their prior forecast of ($1.91). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for AgomAb Therapeutics’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for AgomAb Therapeutics’ FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.72) EPS, FY2029 earnings at ($1.77) EPS and FY2030 earnings at ($1.75) EPS.
AGMB has been the subject of a number of other reports. Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Piper Sandler started coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating for the company. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Finally, Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.50.
AgomAb Therapeutics Stock Performance
AGMB opened at $5.62 on Wednesday. AgomAb Therapeutics has a 52 week low of $5.50 and a 52 week high of $17.82. The business has a fifty day simple moving average of $8.85 and a 200-day simple moving average of $11.60.
Insider Transactions at AgomAb Therapeutics
In other AgomAb Therapeutics news, Director David R. Epstein bought 15,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were acquired at an average cost of $6.90 per share, with a total value of $103,500.00. Following the acquisition, the director directly owned 40,000 shares of the company’s stock, valued at $276,000. The trade was a 60.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Tim Jasper Knotnerus acquired 6,000 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was purchased at an average price of $8.48 per share, for a total transaction of $50,880.00. Following the completion of the transaction, the chief executive officer owned 16,823 shares in the company, valued at $142,659.04. The trade was a 55.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 75,980 shares of company stock valued at $577,112.
About AgomAb Therapeutics
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Recommended Stories
- Five stocks we like better than AgomAb Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
